Prolonged delivery of apomorphine through the buccal mucosa, towards a noninvasive sustained administration method in Parkinson's disease: in vivo investigations in pigs.

  title={Prolonged delivery of apomorphine through the buccal mucosa, towards a noninvasive sustained administration method in Parkinson's disease: in vivo investigations in pigs.},
  author={Constantin Itin and Rinat Komargodski and Dinorah Barasch and Abraham J. Domb and Amnon Hoffman},
  journal={Journal of pharmaceutical sciences},
1 Citations
A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson’s disease
A deep eutectic-based ternary solvent system that self-emulsifies in situ following subcutaneous injection and entraps apomorphine allows a 48-h duration of detectable drug concentration in the plasma of pigs, allowing a remarkable improvement over the clinical comparator.


In Vivo Buccal Delivery of the Peptide Drug Buserelin with Glycodeoxycholate as an Absorption Enhancer in Pigs
The results of this study demonstrate that buccal administration with the use of absorption enhancers is a useful approach for the delivery of peptide drugs such as buserelin.
Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson’s Disease
The population pharmacokinetic-pharmacodynamic data reflect the clinical observations of steep dose-effect curves if apomorphine is used in patients with random ‘on-off’ fluctuations and could be helpful in predicting the clinical effects of apomorphicine in the several subgroups of patients with Parkinson’s disease.
Stepwise Intravenous Infusion of Apomorphine to Determine the Therapeutic Window in Patients with Parkinson's Disease
The stepwise increase and decrease of the intravenous infusion rate is a suitable tool for the establishment of the concentration-effect relation of apomorphine in individual patients, and the finding of a narrow therapeutic window, in which the onset concentrations vary from patient to patient, underlines the need for accurate and individualized dosing.
Creating systemic oral transmucosal drug delivery strategies: Case study of APL-130277
A case study of Cynapsus Therapeutics' APL-130277, a sublingual apomorphine formulation in clinical development for Parkinson's disease exemplifies the scientific, clinical and commercial considerations for systemic oral transmucosal drug delivery.
Conscious and anaesthetised Göttingen mini-pigs as an in-vivo model for buccal absorption – pH-dependent absorption of metoprolol from bioadhesive tablets
A pH-dependent absolute bioavailability of metoprolol when administrated as bioadhesive buccal tablets to anaesthetised mini-pigs was shown, and the anaesthesia was found to delay the time to reach maximal plasma concentration of metobrolol as compared to the conscious pig model when administrating as buccals.
Buccal tissues and cell culture.
The development of a small, thin flexible device that causes minimal disruption to normal activities such as eating, drinking, and talking is the ultimate aim of this area of drug delivery research, and the degree of drug permeation through the buccal mucosa must be determined.
Critical evaluation of permeation enhancers for oral mucosal drug delivery
This article reviews the various categories of permeation enhancers for oral mucosal drug delivery, their mechanism of action, their usefulness, and the limitations associated with their use.